Vcanbio Cell & Gene Engineering Corp., Ltd

Shanghai Stock Exchange 600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -2.64 M

Vcanbio Cell & Gene Engineering Corp., Ltd Net Cash Used Provided By Financing Activities is USD -2.64 M for the year ending December 31, 2023, a -134.90% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Vcanbio Cell & Gene Engineering Corp., Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -1.12 M, a 85.65% change year over year.
Vcanbio Cell & Gene Engineering Corp., Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -7.82 M, a 51.35% change year over year.
Vcanbio Cell & Gene Engineering Corp., Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -16.08 M, a -131.39% change year over year.
Vcanbio Cell & Gene Engineering Corp., Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 51.24 M, a 1,485.77% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Shanghai Stock Exchange: 600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd

CEO	Mr. Hongqi Wang
IPO Date	May 4, 1993
Location	China
Headquarters	Huayuan Industrial Park
Employees	2,209
Sector	Health Care
Industries Biotechnology

Description

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, safe medication guide gene testing for children and adults, disease genetic testing, disease susceptibility gene testing, etc.; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and experimental synthetic agents; and in vitro diagnostic reagents and medical devices. Vcanbio Cell & Gene Engineering Corp., Ltd was founded in 1992 and is based in Tianjin, the People's Republic of China.

Key trends

Past 5 years